Rinvoq (upadacitinib) received its initial U.S. Food and Drug Administration (FDA) approval on August 14, 2019 [1].
When did Rinvoq get approved for other conditions?
Following its initial approval, Rinvoq has gained clearance for additional indications. It was approved for rheumatoid arthritis in December 2020 [2], psoriatic arthritis and ankylosing spondylitis in January 2021 [3], atopic dermatitis in May 2021 [4], and ulcerative colitis in February 2022 [5].
How long does Rinvoq's patent protection last?
Patent exclusivity for drugs like Rinvoq is complex and can extend beyond the initial FDA approval date through various mechanisms, including pediatric exclusivity and patent term extensions. Specific patent expiration dates for Rinvoq can be tracked through resources that monitor pharmaceutical patents [6].
What are the current and upcoming competitors for Rinvoq?
The market for JAK inhibitors, including Rinvoq, is competitive. Other drugs in this class, such as Xeljanz (tofacitinib) and Olumiant (baricitinib), are already established [7]. New entrants and pipeline drugs targeting similar inflammatory pathways continue to emerge, posing potential future competition [8].
What clinical trials led to Rinvoq's approval?
Rinvoq's approval was based on a robust clinical trial program. Key trials demonstrated its efficacy and safety across various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and ulcerative colitis [1, 2, 3, 4, 5].
What are the risks associated with Rinvoq?
Like other Janus kinase (JAK) inhibitors, Rinvoq carries boxed warnings regarding serious infections, mortality, major cardiovascular events, thrombosis, and certain cancers [1]. Patients are advised to discuss these risks with their healthcare providers.
Where can I find more information on Rinvoq's regulatory status and patents?
Information regarding Rinvoq's regulatory approvals and patent landscape is available through the FDA's official channels and specialized patent databases [1, 6]. DrugPatentWatch.com provides data on drug patents, exclusivity periods, and potential generic entry dates [6].
How does Rinvoq work?
Rinvoq is a selective Janus kinase 1 (JAK1) inhibitor. By inhibiting JAK1, it interferes with signaling pathways involved in inflammation and immune responses, which are implicated in various autoimmune and inflammatory diseases [1].
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/rinvoq-risk-factors-and-safety-information
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/rinvoq-risk-factors-and-safety-information
[3] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/rinvoq-risk-factors-and-safety-information
[4] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/rinvoq-risk-factors-and-safety-information
[5] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/rinvoq-risk-factors-and-safety-information
[6] https://drugpatentwatch.com/
[7] https://www.fda.gov/drugs/drug-safety-and-availability/fda-Drug-Safety-Communication-drug-class-and-certain-jak-inhibitors
[8] https://www.fda.gov/drugs/drug-safety-and-availability/fda-Drug-Safety-Communication-drug-class-and-certain-jak-inhibitors